TGFB1 and hepatocellular carcinoma: TGF-β signaling inhibitors could hinder HCC cell growth and progression by inhibiting the EMT process in distinct experiment models, leading to the clinical investigation of the TGF-β inhibitor LY2157299 (phase II clinical trial, Identifier: NCT01246986,http://clinicaltrials.gov) [6, 9].